Cancer News

Superior Overall Survival for Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) compared Chemotherapy in Advanced Non-Small Cell Lung Cancer (11/29/2019)

The Opdivo plus low-dose Yervoy immunotherapy combination improved long-term survival for patients with advanced non-small cell lung cancer (NSCLCC) across PD-L1 expression levels. (3) Both Opdivo and Yervoy are effective for the treatment of many cancers including NSCLC. These drugs are designed to help the immune system recognize and fight cancer. Opdivo belongs to a class of medicines... Continue Reading

Tagrisso Improves Overall Survival in EGFR-Mutation Positive NSCLC (10/04/2019)

Initial treatment with Tagrisso (osimertinib) significantly lengthens overall survival compared to older generation EGFR-TKIs in patients with Ex19del/L858R EGFR mutated advanced non–small cell lung cancer (NSCLC), according to results of the FLAURA clinical trial presented at the ESMO Congress in Oct 2019. (1,2) the median overall survival with osimertinib was 38.6 months compared to 31.8... Continue Reading

Addition of Avastin to Tarceva Doesn’t Improve Outcome in EGF-Positive NSCLC (09/27/2019)

Progression-free survival (PFS) rates with erlotinib therapy plus bevacizumab for EGFR-positive non–small-cell lung cancer (NSCLC) were not superior to those seen with erlotinib monotherapy, according to findings from a phase 2 clinical trial. In the study, Thomas E. Stinchcombe, MD, Duke Cancer Institute, Durham, North Carolina, and colleagues sought to determine whether adding bevacizumab to standard... Continue Reading

Prophylactic Cranial Irradiation Improves Disease-Free Survival and Brain Metastasis Rates for Locally Advanced Non-Small Cell Lung Cancer (03/20/2019)

PHILADELPHIA, PA– Prophylactic cranial irradiation (PCI), a technique used to prevent the clinical development of brain metastases, is established as a standard approach for many patients with small cell lung cancer (SCLC) after initial therapy. While studies established that PCI decreases the incidence of brain metastases for patients with locally advanced non-small cell lung cancer... Continue Reading

November Is National Lung Cancer Awareness Month (10/23/2018)

Treatment advances – lung cancer resources and advocacy are making the difference The month of November brings lung cancer into focus. Over the past few years great strides have been made in the treatment of non-small cell lung cancer due to the advancement of precision cancer medicines and immunotherapy. Lung cancer however remains the second …

Continue reading "November Is National Lung Cancer Awareness Month"

Blood Test Identifies More Treatable Cancer Mutations Than Tissue Biopsy Alone (10/15/2018)

Penn study shows patients with treatable mutations identified by liquid biopsy also largely respond to therapy October 11, 2018 PHILADELPHIA – In one of the largest clinical studies to ever examine the impact of using a blood test to detect treatable mutations in non-small cell lung cancer (NSCLC), researchers from the Abramson Cancer Center of …

Continue reading "Blood Test Identifies More Treatable Cancer Mutations Than Tissue Biopsy Alone"

Overall Health, Not Just Age, is an Important Factor in Treatment of Non-Small Cell Lung Cancer (07/10/2018)

Two clinical studies highlight the importance of evaluating overall health instead of age in the management of lung cancer. In fact, younger patients with non-small cell lung cancer (NSCLC) are more likely to receive treatment than older patients, regardless of overall health and prognosis according to the results of a study published in the Journal of …

Continue reading "Overall Health, Not Just Age, is an Important Factor in Treatment of Non-Small Cell Lung Cancer"

Xalkori Receives FDA Breakthrough Therapy Designation for Treatment of Lung Cancer with MET Alterations (06/05/2018)

The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for Xalkori (crizotinib) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with MET exon 14 alterations with disease progression on or after platinum-based chemotherapy. The FDA’s Breakthrough Therapy designation is intended to expedite the development and review of a medicine …

Continue reading "Xalkori Receives FDA Breakthrough Therapy Designation for Treatment of Lung Cancer with MET Alterations"

Alcensa Provides Longer Symptom Improvement than Xalkori in ALK-positive Lung Cancer (04/24/2018)

CancerConnect News: Alecensa (alectinib) provides longer symptom improvement than Xalkori (crizotinib) in ALK-positive non-small-cell lung cancer (NSCLC), according to results presented at the European Lung Cancer Congress in in Geneva, Switzerland.1 About ALK + NSCLC Lung cancer is the leading cause of cancer death in the U.S. and around the world, highlighting the importance of …

Continue reading "Alcensa Provides Longer Symptom Improvement than Xalkori in ALK-positive Lung Cancer"

Overall Health, Not Just Age, is an Important Factor in Treatment of Non-Small Cell Lung Cancer (04/11/2018)

Younger patients with non-small cell lung cancer (NSCLC) are more likely to receive treatment than older patients, regardless of overall health and prognosis, according to the results of a study published in the Journal of Clinical Oncology. Lung cancer remains the leading cause of cancer death in the United States. Non–small cell lung cancer (NSCLC) …

Continue reading "Overall Health, Not Just Age, is an Important Factor in Treatment of Non-Small Cell Lung Cancer"